PTC Therapeutics (PTCT) Gains as Sarepta's Eteplirsen Approved

September 19, 2016 9:54 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

PTC Therapeutics (NASDAQ: PTCT) gains as Sarepta's eteplirsen gains FDA accelerated approval.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment